Replies to post #212458 on Biotech Values

[ghmm]

SRPT:

This settlement led to the launch of their named patient expanded access program this morning.

http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2287336
http://www.sarepta.com/community/managed-access-program

On the call they said not to expect meaningful revenue till Q4 still I like the aggressive nature of the new CEO.

The guidance for the year increased to 125-130 is still pretty low IMO it would imply 75-80M for Q3+Q4 which is basically no growth given the number of patients now on drug. Granted summer months may have slower uptake perhaps some more missed doses but I think they are (continuing to be) conservative.

This is the afternoon Earnings PR
http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2287336

The call is available here:
http://edge.media-server.com/m/p/tmiout8w/lan/en

[DewDiligence]

BMRN sells $500M* of convertible debt:

http://www.prnewswire.com/news-releases/biomarin-announces-offering-of-450-million-of-senior-subordinated-convertible-notes-due-2024-300500544.html

*Assuming exercise of underwriter’s option.